A Study of Lasmiditan on the Heart in Healthy Participants

Inclusion Criteria: * Body mass index within 18.5 and 29.9 kilograms per meter squared (kg/m²) * In good physical and mental health as determined by the following: * Complete medical history * Complete physical examination * Vital signs including blood pressure (supine and standing), heart rate (supine and standing), respiratory rate, and temperature * Standard 12-lead ECG (triplicate ECG), followed by a 24-hour Holter ECG for arrhythmia monitoring * Clinical laboratory tests Exclusion Criteria: * Any of the following cardiac abnormalities on safety screening ECG: * QTcF interval \>430 milliseconds (ms) for males, \>450 ms for females * Unusual T wave morphology or flattened low voltage T waves * PR interval \>240 ms or \<110 ms * Second-degree or third-degree atrioventricular block * ECG evidence of complete left or right bundle branch block * Intraventricular conduction delay or QRS duration \>110 ms * Supine resting heart rate \<45 beats per minute (bpm) or \>90 bpm * Pathological Q-waves * Evidence of ventricular pre-excitation * Participants with a history of syncope, cardiac arrest, cardiac arrhythmia or torsade de pointes, or structural heart disease * Participants with a family history of Long QT syndrome * History of allergic hypersensitivity to lasmiditan or any component of the formulations * History or current evidence of abuse of any drug substance, licit or illicit, including alcohol; a positive urine screen for drugs of abuse * Participants with a history of postural hypotension or fainting * Participant is not able to understand and comply with study requirements, instructions and study restrictions